Literature DB >> 12511593

A PEST sequence in ABCA1 regulates degradation by calpain protease and stabilization of ABCA1 by apoA-I.

Nan Wang1, Wengen Chen, Patrick Linsel-Nitschke, Laurent O Martinez, Birgit Agerholm-Larsen, David L Silver, Alan R Tall.   

Abstract

Cholesterol-loaded macrophage foam cells are a central component of atherosclerotic lesions. ABCA1, the defective molecule in Tangier disease, mediates the efflux of phospholipids and cholesterol from cells to apoA-I, reversing foam cell formation. In ABCA1, we identified a sequence rich in proline, glutamic acid, serine, and threonine (PEST sequence) that enhances the degradation of ABCA1 by calpain protease and thereby controls the cell surface concentration and cholesterol efflux activity of ABCA1. In an apparent positive feedback loop, apoA-I binds ABCA1, promotes lipid efflux, inhibits calpain degradation, and leads to increased levels of ABCA1. ApoA-I infusion also increases ABCA1 in vivo. These studies reveal a novel mode of regulation of ABCA1 by PEST sequence-mediated calpain proteolysis that appears to be reversed by apolipoprotein-mediated phospholipid efflux. Inhibition of ABCA1 degradation by calpain could represent a novel therapeutic approach to increasing macrophage cholesterol efflux and decreasing atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12511593      PMCID: PMC151839          DOI: 10.1172/JCI16808

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  42 in total

1.  The PEST domain of IkappaBalpha is necessary and sufficient for in vitro degradation by mu-calpain.

Authors:  S D Shumway; M Maki; S Miyamoto
Journal:  J Biol Chem       Date:  1999-10-22       Impact factor: 5.157

2.  Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency.

Authors:  A Brooks-Wilson; M Marcil; S M Clee; L H Zhang; K Roomp; M van Dam; L Yu; C Brewer; J A Collins; H O Molhuizen; O Loubser; B F Ouelette; K Fichter; K J Ashbourne-Excoffon; C W Sensen; S Scherer; S Mott; M Denis; D Martindale; J Frohlich; K Morgan; B Koop; S Pimstone; J J Kastelein; J Genest; M R Hayden
Journal:  Nat Genet       Date:  1999-08       Impact factor: 38.330

Review 3.  Calpain inhibitors as therapeutic agents in nerve and muscle degeneration.

Authors:  A Stracher
Journal:  Ann N Y Acad Sci       Date:  1999-11-28       Impact factor: 5.691

4.  Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor.

Authors:  P Costet; Y Luo; N Wang; A R Tall
Journal:  J Biol Chem       Date:  2000-09-08       Impact factor: 5.157

5.  Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans.

Authors:  M Eriksson; L A Carlson; T A Miettinen; B Angelin
Journal:  Circulation       Date:  1999-08-10       Impact factor: 29.690

6.  Concentrations of electrophoretic and size subclasses of apolipoprotein A-I-containing particles in human peripheral lymph.

Authors:  M N Nanjee; C J Cooke; W L Olszewski; N E Miller
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-09       Impact factor: 8.311

7.  ABCA1 is the cAMP-inducible apolipoprotein receptor that mediates cholesterol secretion from macrophages.

Authors:  J F Oram; R M Lawn; M R Garvin; D P Wade
Journal:  J Biol Chem       Date:  2000-11-03       Impact factor: 5.157

8.  Specific binding of ApoA-I, enhanced cholesterol efflux, and altered plasma membrane morphology in cells expressing ABC1.

Authors:  N Wang; D L Silver; P Costet; A R Tall
Journal:  J Biol Chem       Date:  2000-10-20       Impact factor: 5.157

Review 9.  Atherosclerosis.

Authors:  A J Lusis
Journal:  Nature       Date:  2000-09-14       Impact factor: 49.962

10.  Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers.

Authors:  J J Repa; S D Turley; J A Lobaccaro; J Medina; L Li; K Lustig; B Shan; R A Heyman; J M Dietschy; D J Mangelsdorf
Journal:  Science       Date:  2000-09-01       Impact factor: 47.728

View more
  77 in total

1.  Altered trafficking and stability of polycystins underlie polycystic kidney disease.

Authors:  Yiqiang Cai; Sorin V Fedeles; Ke Dong; Georgia Anyatonwu; Tamehito Onoe; Michihiro Mitobe; Jian-Dong Gao; Dayne Okuhara; Xin Tian; Anna-Rachel Gallagher; Zhangui Tang; Xiaoli Xie; Maria D Lalioti; Ann-Hwee Lee; Barbara E Ehrlich; Stefan Somlo
Journal:  J Clin Invest       Date:  2014-11-03       Impact factor: 14.808

2.  Naturally occurring variant of mouse apolipoprotein A-I alters the lipid and HDL association properties of the protein.

Authors:  Timothy J Sontag; Ronald Carnemolla; Tomas Vaisar; Catherine A Reardon; Godfrey S Getz
Journal:  J Lipid Res       Date:  2012-03-08       Impact factor: 5.922

3.  Large putative PEST-like sequence motif at the carboxyl tail of human calcium receptor directs lysosomal degradation and regulates cell surface receptor level.

Authors:  Xiaolei Zhuang; John K Northup; Kausik Ray
Journal:  J Biol Chem       Date:  2011-12-12       Impact factor: 5.157

4.  An apoA-I mimetic peptibody generates HDL-like particles and increases alpha-1 HDL subfraction in mice.

Authors:  Shu-Chen Lu; Larissa Atangan; Ki Won Kim; Michelle M Chen; Renee Komorowski; Carolyn Chu; Joon Han; Sylvia Hu; Wei Gu; Murielle Véniant; Minghan Wang
Journal:  J Lipid Res       Date:  2012-01-27       Impact factor: 5.922

Review 5.  The interaction of ApoA-I and ABCA1 triggers signal transduction pathways to mediate efflux of cellular lipids.

Authors:  Guo-Jun Zhao; Kai Yin; Yu-Chang Fu; Chao-Ke Tang
Journal:  Mol Med       Date:  2012-03-27       Impact factor: 6.354

6.  Advanced glycation of apolipoprotein A-I impairs its anti-atherogenic properties.

Authors:  A Hoang; A J Murphy; M T Coughlan; M C Thomas; J M Forbes; R O'Brien; M E Cooper; J P F Chin-Dusting; D Sviridov
Journal:  Diabetologia       Date:  2007-06-20       Impact factor: 10.122

Review 7.  Proteases in cardiometabolic diseases: Pathophysiology, molecular mechanisms and clinical applications.

Authors:  Yinan Hua; Sreejayan Nair
Journal:  Biochim Biophys Acta       Date:  2014-05-09

8.  Inhibition of ABCA1 protein degradation promotes HDL cholesterol efflux capacity and RCT and reduces atherosclerosis in mice.

Authors:  LinZhang Huang; BaoYan Fan; Ang Ma; Philip W Shaul; HaiBo Zhu
Journal:  J Lipid Res       Date:  2015-03-11       Impact factor: 5.922

Review 9.  Emerging roles of calpain proteolytic systems in macrophage cholesterol handling.

Authors:  Takuro Miyazaki; Akira Miyazaki
Journal:  Cell Mol Life Sci       Date:  2017-04-21       Impact factor: 9.261

10.  Calpain-6 confers atherogenicity to macrophages by dysregulating pre-mRNA splicing.

Authors:  Takuro Miyazaki; Kazuo Tonami; Shoji Hata; Toshihiro Aiuchi; Koji Ohnishi; Xiao-Feng Lei; Joo-Ri Kim-Kaneyama; Motohiro Takeya; Hiroyuki Itabe; Hiroyuki Sorimachi; Hiroki Kurihara; Akira Miyazaki
Journal:  J Clin Invest       Date:  2016-08-15       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.